AKTX - Company ID 0001541157
The table below shows Akari Therapeutics Plc's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.69M | $2.77M | - | $2.71M | $2.58M | $2.25M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.32M |
| $3.59M |
| $2.95M |
| $3.30M |
| $3.35M |
| $2.73M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | - |
| Total assets | $38.62M | $33.89M | $45.38M | $50.91M | $50.96M | $2.73M |
| Accounts payable | $9.40M | $8.64M | $10.84M | $11.61M | $13.07M | $4.78M |
| Total current liabilities | $13.94M | $13.41M | $15.57M | $17.14M | $20.91M | $9.43M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $20.03M | $19.51M | $22.69M | $25.31M | $29.21M | - |
| Retained earnings | -$283.81M | -$279.00M | -$259.25M | -$252.85M | -$250.96M | -$243.48M |
| Total equity | $18.59M | $14.38M | $22.69M | $25.61M | $21.75M | -$6.69M |